Cytosine-phosphate-guanosine-DNA Induces CD274 Expression in Human B Cells and Suppresses T Helper Type 2 Cytokine Production in Pollen Antigen-stimulated CD4-positive Cells
Overview
Affiliations
Co-stimulatory molecules are important for regulating T cell activation and immune response. CD274 [programmed death ligand 1 (PD-L1), B7-H1] has emerged as an important immune modulator that can block T cell receptor signalling. We have investigated whether PD-L1 and other co-stimulatory ligands could be expressed in human B cells stimulated by cytosine-phosphate-guanosine (CpG)-DNA. CpG-DNA strongly induced the co-inhibitory molecule ligand, PD-L1, of human B cells. Results show that nuclear factor-kappa B (NF-κB) signalling is involved directly in CpG-DNA-induced PD-L1 expression in human B cells. We sought to determine the effect of CpG-DNA-treated B cells on T helper type 2 (Th2) cytokine production in Cry j 1 (Japanese pollen antigen)-stimulated human CD4-positive cells from patients with seasonal allergic rhinitis caused by Japanese cedar pollen. CpG-DNA-treated B cells reduced Cry j 1-induced interleukin (IL)-5 and IL-13 production in CD4-positive cells. When the binding of PD-1 to PD-L1 was inhibited by PD-1-immunoglobulin (Ig), this chimera molecule reversed the previously described reductions in IL-5 and IL-13 production. In contrast, the CpG B-treated B cells increased both interferon (IFN)-γ and IL-12 production in the presence of Cry j 1-stimulated CD4-positive cells. CpG-DNA simultaneously reduced the expression of B7RP-1 [also known as inducible co-stimulator ligand (ICOSL), B7-H2] and the ligand of CD30 (CD30L). These results indicate that CpG-DNA induces co-inhibitory molecule ligand PD-L1 expression in human B cells and PD-L1 can suppress Th2 cytokine production in Cry j 1-stimulated CD4-positive cells, while CpG-DNA increased Th1 cytokine production and reduced the expression of co-stimulatory molecule ligands that can promote Th2 inflammatory responses.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S Nat Commun. 2025; 16(1):1041.
PMID: 39863584 PMC: 11762753. DOI: 10.1038/s41467-025-56318-7.
Jeon Y, Kang T, Lee W, Jung S, Kim Y Biomed Res Int. 2023; 2023:1317998.
PMID: 37206297 PMC: 10191743. DOI: 10.1155/2023/1317998.
New approaches to immunotherapy in house dust mite allergy.
Kim I Clin Exp Pediatr. 2022; 66(4):161-168.
PMID: 36397261 PMC: 10080380. DOI: 10.3345/cep.2022.00479.
Allergen Immunotherapy: Current and Future Trends.
Pavon-Romero G, Parra-Vargas M, Ramirez-Jimenez F, Melgoza-Ruiz E, Serrano-Perez N, Teran L Cells. 2022; 11(2).
PMID: 35053328 PMC: 8774202. DOI: 10.3390/cells11020212.
Regulatory B Cell Therapy in Kidney Transplantation.
Garcia S, Sandoval-Hellin N, Franquesa M Front Pharmacol. 2021; 12:791450.
PMID: 34950041 PMC: 8689004. DOI: 10.3389/fphar.2021.791450.